Browse Health


Education ?

Medical School
Dr. Vaishampayan Memorial Medical College (1988)
Foreign school

Awards & Distinctions ?

Best Doctors in America (2013)
Hour Detroit Magazine's Top Docs (2012)
Best Doctors in America (2014)
Hour Detroit Magazine's Top Docs (2014)
Hour Detroit Magazine's Top Docs (2013)
Hour Detroit Magazine's Top Docs (2010)
Hour Detroit Magazine's Top Docs (2011)
Fellow, American College of Surgeons, Hour Detroit Magazine's Top Docs (2010), Hour Detroit Magazine's Top Docs (2011), Member, American Society of Breast Surgeons
American Board of Surgery

Affiliations ?

Dr. Dekhne is affiliated with 2 hospitals.

Hospital Affiliations



  • Beaumont Hospital, Grosse Pointe
    468 Cadieux Rd, Grosse Pointe, MI 48230
    Top 25%
  • Beaumont Hospital, Royal Oak
    3601 W 13 Mile Rd, Royal Oak, MI 48073
    Top 25%
  • Publications & Research

    Dr. Dekhne has contributed to 2 publications.
    Title Optimal Use of Re-excision in Patients Diagnosed with Early-stage Breast Cancer by Excisional Biopsy Treated with Breast-conserving Therapy.
    Date January 2010
    Journal Annals of Surgical Oncology

    The goal of the current study is to help refine guidelines for the need for re-excision and the appropriate amount of breast tissue to re-excise in patients with early breast cancer following excisional breast biopsy when treated with breast-conserving therapy (BCT).

    Title Molecular Classification System Identifies Invasive Breast Carcinoma Patients Who Are Most Likely and Those Who Are Least Likely to Achieve a Complete Pathologic Response After Neoadjuvant Chemotherapy.
    Date November 2007
    Journal Cancer

    BACKGROUND: The molecular classification system categorizes invasive breast carcinomas according to their key driving biomarkers. In the current study, the authors evaluated whether response to neoadjuvant chemotherapy was correlated with the molecular classification groups. METHODS: Using immunohistochemistry, the molecular classification group (luminal-A, luminal-B, HER-2-variant, HER-2-classic, and basal phenotype) was retrospectively determined in 68 breast cancer patients who received neoadjuvant treatment. RESULTS: A total of 28 carcinoma patients (41.2%) achieved a compete pathologic response (CPR), including 2 of 15 patients classified as having luminal-A (13.3%), 4 of 16 patients classified as having luminal-B (25.0%), 10 of 12 patients classified as having HER-2-classic (83.3%), none of the 4 patients classified as having HER-2-variant, and 12 of 21 patients classified as having basal phenotype (57.1%) neoplasms. The CPR rate among patients with the HER-2-classic and basal neoplasms was 67% (22 of 33 neoplasms), compared with 17.1% (6 of 35 neoplasms) in the non-HER-2-classic/basal combined group (P < .001). Eleven carcinomas were initially diagnosed as invasive lobular carcinomas (pleomorphic and classic), 4 of which were luminal-A, 4 of which were luminal-B, 2 of which were HER-2-classic, and 1 of which was basal. On review, only 3 of these 11 cases remained classified as classic lobular carcinoma, all of which were classified as luminal-A, and none of these patients achieved a CPR. Four of the other 8 patients achieved a CPR. CONCLUSIONS: The molecular classification system is useful for identifying carcinoma patients who are most likely and those who are least likely to achieve a CPR. In the current study, all the morphologically classic lobular carcinomas were classified as luminal-A neoplasms, which may explain the low rate of CPR reported.

    Similar doctors nearby

    Dr. Mark McMurray

    Orthopaedic Surgery
    28 years experience
    Royal Oak, MI

    Dr. Nicholas Tepe

    32 years experience
    Royal Oak, MI

    Dr. Michelle Veenstra

    Royal Oak, MI

    Dr. Wesley Barnes

    Royal Oak, MI

    Dr. Jared Weir

    Orthopaedic Surgery
    Royal Oak, MI

    Dr. David Pridmore

    Royal Oak, MI
    Search All Similar Doctors